Skan Group Ag · SIX:SKAN
Skan — IPO Roadshow (October 2021)
23 slides from Skan's IPO roadshow presentation, Oct 7, 2021
Slide 1: SKAN Group Media Conference Presentation
SKAN Group Media Conference Presentation 7 October 2021
Slide 2: Today's presenters
Today’s presenters SKAN Gert Thoenen Thomas Huber Burim Maraj Chairman Group CEO Group CFO Chairman since 2021 Joined SKAN in 1996 Joined SKAN in 2008 Group CEO since 2017 Group CFO since 2018 − Senior partner at Lenz Caemmerer − Previously Chief Marketing Officer and − Previously Chief Officer IT &
Slide 3: SKAN – longstanding heritage in aseptic manufacturing
SKAN – longstanding heritage in aseptic manufacturing SKAN equipment and processes Revenues 2020A: CHF 207m(1) Foundation of SKAN AG as trading company for Scandinavian BV Holding invests in healthcare equipment SKAN as part of a succession New logo financing Organizational milestones In the 1990s,
Slide 4: Transaction structure
SKAN Transaction structure 1 Pre-IPO legal structure 2 Quasi-merger (immediately prior to 3 After IPO listing on SIX Swiss Exchange) BV Holding AG Former BV Holding shareholders Other shareholders Pre-IPO shareholders IPO investors listed on BX Swiss / other shareholders of SKAN Holding Sell-down to
Slide 5: SKAN's investment highlights
SKAN’s investment highlights SKAN 1 Market leader globally for 2 Technology & innovation 3 Strategically positioned in a 4 Significant barriers to high-end aseptic process leadership with first-to- highly dynamic & rapidly entry due to regulatory solutions catering the global market solutions and gr
Slide 6: Key challenge for (bio-)pharmaceutical products
1 Key challenge for (bio-)pharmaceutical products SKAN Key challenge: Products: In particular true for: Medical safety Injectables High-value biopharma drugs Medication safety is key and (cross-) Cancer drugs (ADC, Cytotoxics) contamination unacceptable Cell & gene therapy (Advanced Risk of signific
Slide 7: SKAN is global market leader in high-end isolator solutions
1 SKAN is global market leader in high-end isolator solutions SKAN Solution: Medication sterility Traditional pharma Cleanroom Pharma products mainly + Filling / closing in cleanroom with terminal sterilization chemical based - Inappropriate for complex biopharmaceuticals Cleanroom Terminal environm
Slide 8: Technology & innovation leadership
2 Technology & innovation leadership SKAN Technology leadership & foresight Fabrication know-how Electron beam transfer Award winning design HVAC engineering & air flow modelling allows SKAN to be the market defining player Continuous active contribution to new guidelines & regulations through indus
Slide 9: Highly dynamic niche market with strong end market growth
3 Highly dynamic niche market with strong end market growth SKAN Strong growth of aseptic manufacturing(1) Key growth drivers Isolator market by value (EURm) Underlying biopharma industry growth: CAGR Global pharmaceutical industry: +4.5% p.a. (CAGR 2021-2026F)(2) (2016-20) (20-26F) Cell & gene ther
Slide 10: Constantly expanding addressable market
3 Constantly expanding addressable market SKAN Aseptic manufacturing market by technology Isolator Isolators RABS Cleanroom equipment Integrated, fully-automated robotics (1) (1) (2) 2015 2020 2025 Shift from cleanroom towards isolator solutions… … and further to integrated aseptic manufacturing Key
Slide 11: SKAN's leadership position is underpinned by high entry barriers and compelling value proposition
4 SKAN’s leadership position is underpinned by high entry SKAN barriers and compelling value proposition Entry barriers SKAN’s value proposition Key purchasing criteria Technological edge ✓ Mastery of difficult to replicate know-how on highest- Product quality / reliability ✓ performance isolators B
Slide 12: Comprehensive portfolio for global (bio-)pharma customers
5 Comprehensive portfolio for global (bio-)pharma customers SKAN Cleanroom Customized and modular isolators Integrated processes Business Business Business Pure contrib. Process Solutions contrib. Integrated Process Solutions contrib. Solutions Pure Solutions Customized Solutions (“CusSol”) System S
Slide 13: One-stop-shop across the entire lifecycle of SKAN's mission-critical aseptic process solutions
5 One-stop-shop across the entire lifecycle of SKAN’s mission- SKAN critical aseptic process solutions Year 0 Time Year 1-2 Year 2-3 Year 2-20 Year 20 (0.5y) Product lifecycle Design & engineering Manufacturing & Commissioning & Global lifecycle End-of-life services assembling qualification support
Slide 14: Strong and growing global footprint
5 Strong and growing global footprint SKAN Allschwil Gembloux HQ SKAN locations Headquarters / Sales & services coverage Production site / AT production sites ▪ Aseptic Filling ▪ Engineering, sales, Gembloux equipment (Closed service, assembly, BE Vial® Technology) R&D, laboratories ▪ Approx. 3,590
Slide 15: Excellent financial profile with above-market growth and high revenue visibility
6 Excellent financial profile with above-market growth and high SKAN revenue visibility Net revenue & order intake EBITDA Consistent, above-market revenue (CHFm) EBITDA (CHFm) and EBITDA margin (%) growth (+31% CAGR 2018-2020)(1) 171 183 226 16.6% Strong revenue visibility based on order backlog of
Slide 16: H1 2021A supporting strong growth outlook
6 H1 2021A supporting strong growth outlook SKAN Net revenue(1) Order intake (CHFm) (CHFm) Double-digit growth at group level vs. H1 2020A. Pronounced +33.0% 156.8 momentum in Services & +10.2% 103.1 93.6 y-o-y y-o-y 117.9 Consumables segment (+20.0% y-o-y) in-line with SKAN’s +7.3% 77.6 121.7 corpo
Slide 17: Experienced, entrepreneurial management and highly qualified workforce loyal to the firm
7 Experienced, entrepreneurial management and highly qualified SKAN workforce loyal to the firm Experienced >80 combined years at SKAN Highly qualified and dedicated workforce management team approx. 180 combined years in the industry “Together always one step ahead” Loyal, increasing workforce(1) T
Slide 18: Clear growth strategy
8 Clear growth strategy SKAN Objectives: Continue growth track-record Increase recurring revenue base Expand profitability 1 2 Expand addressable 3 Increase exposure to 4 Accelerate digital Fortify market leadership market towards integrated after-market services & transformation process systems con
Slide 19: Financial targets and outlook
8 Financial targets and outlook SKAN Metric 2021E Targets(1) Mid-Term Outlook Group net revenue growth 9-11%(3) Mid-teens Segment net revenue growth(2) E&S S&C E&S S&C Gradually increase profitability level to upper teens in the EBITDA margin 13-15%(4) mid-term. Potential for further increase beyond
Slide 20: Planned investments
8 Planned investments SKAN Investment split SKAN is committed to invest significantly in its future growth beyond the mid-term guidance, as expressed by the company’s targeted growth capex which is expected to amount to CHF 100-120m Expansion of (cumulative) over the mid-term production capacity Wit
Slide 21: Together always one step ahead!
SKAN Together always one step ahead! October 2021 21
Slide 22: Disclaimer
SKAN Disclaimer NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. This presentation, which includes oral statements made at the
Slide 23: Thank you
% , P 4 a ~ : E p ~ A - 7 ‘ ; . ‘ - aN a ij | ea 5 “Thank you %